The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

Paolo A. Ascierto; Christian Blank; Alexander M. Eggermont; Claus Garbe; Jeffrey E. Gershenwald; Omid Hamid; Axel Hauschild; Jason J. Luke; Janice M. Mehnert; Jeffrey A. Sosman; Hussein A. Tawbi; Mario Mandalà; Alessandro Testori; Corrado Caracò; Iman Osman; Igor Puzanov

doi:10.1186/s12967-023-04100-y

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

Paolo A. Ascierto^*, Christian Blank, Alexander M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. Luke, Janice M. Mehnert, Jeffrey A. Sosman, Hussein A. Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov

^*Corresponding author for this work

Department of Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-lymphocyte-activation gene (LAG)-3 therapy or ipilimumab in combination with anti-programmed death (PD)-1 therapy, whether anti-PD-1 monotherapy is still acceptable as a comparator arm in clinical trials, whether adjuvant treatment of melanoma is still a useful treatment option, the role of adjuvant therapy in stage II melanoma, what role surgery will continue to have in the treatment of melanoma. As is customary in the Melanoma Bridge Great Debates, the speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect personal views. Audiences voted in favour of either side of the argument both before and after each debate.

Original language	English
Article number	265
Journal	Journal of Translational Medicine
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12967-023-04100-y
Publication status	Published - Dec 2023

Keywords

Adjuvant
Anti-PD-1
Immunotherapy
Melanoma
Neoadjuvant
Surgery
Targeted therapy

Access to Document

10.1186/s12967-023-04100-yLicence: CC BY

s12967-023-04100-yFinal published version, 1.09 MBLicence: CC BY

Cite this

Ascierto, P. A., Blank, C., Eggermont, A. M., Garbe, C., Gershenwald, J. E., Hamid, O., Hauschild, A., Luke, J. J., Mehnert, J. M., Sosman, J. A., Tawbi, H. A., Mandalà, M., Testori, A., Caracò, C., Osman, I., & Puzanov, I. (2023). The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022. Journal of Translational Medicine, 21(1), Article 265. https://doi.org/10.1186/s12967-023-04100-y

@article{e92e4365d9244662a6c364c6d6bc8bd1,

title = "The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022",

abstract = "The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-lymphocyte-activation gene (LAG)-3 therapy or ipilimumab in combination with anti-programmed death (PD)-1 therapy, whether anti-PD-1 monotherapy is still acceptable as a comparator arm in clinical trials, whether adjuvant treatment of melanoma is still a useful treatment option, the role of adjuvant therapy in stage II melanoma, what role surgery will continue to have in the treatment of melanoma. As is customary in the Melanoma Bridge Great Debates, the speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect personal views. Audiences voted in favour of either side of the argument both before and after each debate.",

keywords = "Adjuvant, Anti-PD-1, Immunotherapy, Melanoma, Neoadjuvant, Surgery, Targeted therapy",

author = "Ascierto, {Paolo A.} and Christian Blank and Eggermont, {Alexander M.} and Claus Garbe and Gershenwald, {Jeffrey E.} and Omid Hamid and Axel Hauschild and Luke, {Jason J.} and Mehnert, {Janice M.} and Sosman, {Jeffrey A.} and Tawbi, {Hussein A.} and Mario Mandal{\`a} and Alessandro Testori and Corrado Carac{\`o} and Iman Osman and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1186/s12967-023-04100-y",

language = "English",

volume = "21",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central",

number = "1",

}

Ascierto, PA, Blank, C, Eggermont, AM, Garbe, C, Gershenwald, JE, Hamid, O, Hauschild, A, Luke, JJ, Mehnert, JM, Sosman, JA, Tawbi, HA, Mandalà, M, Testori, A, Caracò, C, Osman, I & Puzanov, I 2023, 'The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022', Journal of Translational Medicine, vol. 21, no. 1, 265. https://doi.org/10.1186/s12967-023-04100-y

TY - JOUR

T1 - The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

AU - Ascierto, Paolo A.

AU - Blank, Christian

AU - Eggermont, Alexander M.

AU - Garbe, Claus

AU - Gershenwald, Jeffrey E.

AU - Hamid, Omid

AU - Hauschild, Axel

AU - Luke, Jason J.

AU - Mehnert, Janice M.

AU - Sosman, Jeffrey A.

AU - Tawbi, Hussein A.

AU - Mandalà, Mario

AU - Testori, Alessandro

AU - Caracò, Corrado

AU - Osman, Iman

AU - Puzanov, Igor

PY - 2023/12

Y1 - 2023/12

N2 - The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-lymphocyte-activation gene (LAG)-3 therapy or ipilimumab in combination with anti-programmed death (PD)-1 therapy, whether anti-PD-1 monotherapy is still acceptable as a comparator arm in clinical trials, whether adjuvant treatment of melanoma is still a useful treatment option, the role of adjuvant therapy in stage II melanoma, what role surgery will continue to have in the treatment of melanoma. As is customary in the Melanoma Bridge Great Debates, the speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect personal views. Audiences voted in favour of either side of the argument both before and after each debate.

AB - The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-lymphocyte-activation gene (LAG)-3 therapy or ipilimumab in combination with anti-programmed death (PD)-1 therapy, whether anti-PD-1 monotherapy is still acceptable as a comparator arm in clinical trials, whether adjuvant treatment of melanoma is still a useful treatment option, the role of adjuvant therapy in stage II melanoma, what role surgery will continue to have in the treatment of melanoma. As is customary in the Melanoma Bridge Great Debates, the speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect personal views. Audiences voted in favour of either side of the argument both before and after each debate.

KW - Adjuvant

KW - Anti-PD-1

KW - Immunotherapy

KW - Melanoma

KW - Neoadjuvant

KW - Surgery

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85152863702&partnerID=8YFLogxK

U2 - 10.1186/s12967-023-04100-y

DO - 10.1186/s12967-023-04100-y

M3 - Article

C2 - 37072748

AN - SCOPUS:85152863702

SN - 1479-5876

VL - 21

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

IS - 1

M1 - 265

ER -

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this